Eli Lilly Shares Rise on Analyst Upgrade Amid Medicare Obesity Drug Coverage Expansion
Analysts at Leerink raised their price target for Eli Lilly by 10% to $1,232 following the anticipated expansion of obesity drug sales in international markets and upcoming U.S. Medicare coverage starting July 1. The new temporary program will allow eligible patients access to GLP-1 drugs like Foundayo and Zepbound at a reduced cost.
Tickers: $AAPL $AMZN $GOOGL $LLY $META $MSFT $MU
Topics: Eli Lilly GLP-1 drugs Medicare coverage Nasdaq performance S&P 500 semiconductor industry